Overview of the 2026 Physician Fee Schedule for UltraMIST
In a significant update, Sanuwave Health, Inc. (NASDAQ: SNWV), renowned for its advanced FDA-approved wound care solutions, has shared pertinent information about the recently published final rule from the Centers for Medicare & Medicaid Services (CMS) regarding the 2026 Physician Fee Schedule. This schedule delineates the reimbursement rates applicable for the upcoming calendar year, affecting various CPT codes, including 97610, which is specifically associated with the UltraMIST procedure.
UltraMIST Reimbursement Insights
The reimbursement rates for the UltraMIST procedure (CPT code 97610) remain substantially unchanged when compared to the 2025 rates, with costs for treatment provided in physician offices, long-term care facilities, hospitals, and home visits remaining within a modest range of $2 to $4. This level of consistency is encouraging for healthcare providers, particularly as Sanuwave previously expressed expectations of similar outcomes in their preliminary revenue report.
CEO Remarks on 2026 Rates
Sanuwave's CEO, Morgan Frank, addressed inquiries from both investors and healthcare providers concerning reimbursement rates for UltraMIST in 2026. He stated, "Final 2026 rates for 97610 align with the proposed rule and with our earlier expectations. Changes for the new year should be less than 1%, with many providers likely experiencing a slight increase in reimbursement. We look forward to discussing this in detail during our upcoming third quarter earnings call." This statement reflects a positive outlook regarding reimbursement stability in the field of wound care.
Implications for Healthcare Providers
The stability of reimbursement rates for the UltraMIST procedure can have significant implications for healthcare providers who utilize this technology. With a minimal change expected in payments, providers can plan their budgets and patient care strategies more effectively. This assurance allows them to focus not only on the quality of care but also on expanding their treatment options for patients requiring advanced wound care solutions.
Sanuwave's Commitment to Innovation
Sanuwave Health continues to explore innovative advancements in wound care, with the UltraMIST system leading the way. As a company, Sanuwave is dedicated to enhancing patient outcomes through effective technologies and treatment protocols. The stability in reimbursement rates reaffirms the confidence in their advanced offerings.
Future Discussions and Investor Communication
As the healthcare landscape continues to evolve, Sanuwave remains committed to keeping its stakeholders informed. The company plans to provide further updates and detailed discussions about these reimbursement rates during earnings calls and other communication channels. Keeping investors and providers informed not only builds trust but promotes collaboration within the healthcare community.
Frequently Asked Questions
What is the final reimbursement rate for the UltraMIST procedure in 2026?
The reimbursement rates for the UltraMIST procedure (CPT code 97610) for 2026 remain largely unchanged, with costs for treatment in various settings consistent within $2-4 compared to 2025.
Who is Sanuwave Health, Inc.?
Sanuwave Health, Inc. is a leading provider of next-generation FDA-approved wound care products, with a strong focus on innovative techniques and technologies aimed at improving patient outcomes.
How does the 2026 Physician Fee Schedule affect healing treatments?
The 2026 Physician Fee Schedule establishes reimbursement rates, which directly impact how healthcare providers deliver treatments and manage their financial planning for care services.
What are the expectations for reimbursement in 2026 according to the CEO?
According to Morgan Frank, Sanuwave's CEO, the expectations are for changes to be less than 1%, with many providers seeing a slight increase in their reimbursement rates for the UltraMIST procedure.
How can I get in touch with Sanuwave for more information?
For further inquiries, you can contact Sanuwave Health via email at investors@sanuwave.com.
